UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Online Course
accredited
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Chronic pancreatitis

Julia Mayerle, Georg Beyer

Summary

AI Generated

An online course on chronic pancreatitis covers definition, epidemiology, diagnosis, staging, and management including endoscopic and surgical approaches for gastroenterologists in training and other healthcare professionals.

  • Chronic pancreatitis is a severe fibroinflammatory disorder of the pancreas with high morbidity and mortality, rising global incidence, and poorly understood pathogenesis despite progress in identifying risk factors.
  • The course addresses aetiology, epidemiology, progression, natural history, diagnosis and staging of chronic pancreatitis.
  • Management topics include pain management, pancreatic exocrine insufficiency, endoscopic therapy, surgical therapy, bile duct obstruction, and pseudocysts.
  • Two clinical cases are included to allow application of knowledge in real-life scenarios.
  • The course is suitable for gastroenterologists in training, physicians and surgeons in other disciplines, nurses, biotechnicians, and advanced-years medical students with an interest in gastroenterology.
Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Overview

Chronic pancreatitis is a severe fibroinflammatory disorder of the pancreas that has a high associated morbidity and mortality. The number of hospitalizations for chronic pancreatitis has markedly increased and the global incidence of the disease continues to rise. Even though progress has been made in identifying common risk factors for chronic pancreatitis, the pathogenesis of the disease remains poorly understood.

This online course covers the definition of chronic pancreatitis, mortality, socioeconomic effect, aetiology and epidemiology, diagnosis and staging, management and the occurrence of bile duct obstruction and pseudocysts. Two clinical cases are also included, allowing application of knowledge in real-life scenarios. 

Learning objectives


To become familiar with:

  • The definition of chronic pancreatitis and its symptoms
  • The aetiology and epidemiology of chronic pancreatitis
  • The progression and natural history of chronic pancreatitis
  • Diagnosis and staging of chronic pancreatitis
  • Pain management and management of pancreatic exocrine insufficiency
  • Endoscopic therapy
  • Surgical therapy

Target audience

This course is suitable for gastroenterologists in training, but is also appropriate for physicians and surgeons in other disciplines, as well as nurses, biotechnicians and advanced-years’ medical students who have an interest in gastroenterology. 

Reviewed & updated April 2024

Event

Chronic pancreatitis

Topics

Pancreas

Accreditation status

accredited

Duration

1 hour

Published

2017

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

UEG Poster
New
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Jakob Vielhauer 1, Tobias Jens 1, Liva Rudroff 1, Marlies Vornhülz 1, Simon Sirtl 1, Hans Stubbe 1, Julia Mayerle 1, Georg Beyer 1

Affiliations

1 LMU Klinikum Munich, Munich, Germany

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Pancreatic exocrine insufficiency (PEI) is routinely evaluated via fecal elastase-1 (FE-1) testing, a simple, non-invasive tool that provides an indirect measure of pancreatic function. However, low FE-1 values are frequently encountered in outpatients referred for diarrhea workup, where the underlying cause may be non-pancreatic, i.e. microscopic colitis, celiac disease or irritable bowel syndrome. As a result, a substantial number of patients undergo extensive diagnostic workup despite ultimately having benign, non-pancreatic etiologies. In our pancreatic disease outpatient service, patients with low FE-1 results are further evaluated through a multimodal diagnostic workup designed to distinguish true pancreatic dysfunction from benign causes.

Aims & Methods

The aim of this retrospective analysis is to outline the necessary, yet reasonable diagnostic work-up for patients presenting to the pancreatic outpatient service and pancreatic involvement is unlikely the reason for reduced FE-1 levels. Furthermore, comparison of the outpatient cohort with rule-out of pancreatic diseases to those patients with true PEI (i.e. due to chronic pancreatitis) shall clarify important features for differentiation.
Methods: Patient data from electronic patient health records treated at the LMU Klinikum Munich, a referral centre for pancreatic diseases, were retrospectively collected. In total, 250 patients were included of which 150 presented for evaluation of decreased FE-1. After analysis of the 150 cases presenting for evaluation of reduced FE-1 levels, an interim analysis was conducted of which the results are discussed here.

Results

Aetiologically, patients with reduced FE-1 levels and no pancreatic cause suffered predominantly from lactose and fructose intolerance, inflammatory bowel disease or small intestinal bacterial overgrowth (SIBO).
FE-1 measurements of patients with confirmed exocrine insufficiency due to pancreatic disease and those without pathological findings of the pancreas showed similar levels. Furthermore, the levels of nutritional deficits were slightly more frequent in the group of pancreatic disease. Concerning laboratory values, no significant changes could be detected for delineating the groups. Imaging could clearly differentiate between the groups of non-pancreatic and pancreatic diseases with all three modalities (CT, MRI, EUS) good sepratation whilst MRI and EUS found significantly more pathologies compares to CT scan.

Conclusion

FE-1 is not a suitable screening tool for exocrine insufficiency as reductions are highly non-specific. Laboratory values cannot solely differentiate between pancreatic and non-pancreatic disease, for which imaging is needed. Here, MRI and EUS showed superiority compared to CT scan. After final data integration, validation of a minimal diagnostic workup for safe identification of non-pancreatic cause of reduced FE-1 measurements will be conducted and presented at the UEG week.

Conference

UEG Week Barcelona 2026

Topics

Pancreas

Submission format

Abstract

Session

PANCREAS (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

UEG Poster
New
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Gizem Sultan Kürtül 1, Orhan Sezgin 2, Damla Hazal Sucu 2

Affiliations

1 Niğde Training and Research Hospital, Nigde, Türkiye

2 Mersin University, Mersin, Türkiye

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

To investigate the frequency of pancreatic exocrine insufficiency (PEI), as well as its associated risk factors and clinical characteristics, in patients presenting to the outpatient gastroenterology clinic with common gastrointestinal symptoms (GI) symptoms such as abdominal pain, bloating, and alterations in bowel habits.

Aims & Methods

In this retrospective study, 310 patients with non-specific GI symptoms were evaluated. Demographics, biochemical markers, fecal elastase-1 (FE-1) levels, ultrasonographic findings, and Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) scores were analyzed. PEI was defined as FE-1 <200 µg/mL; <100 µg/ml indicating severe deficiency.

Results

Variable
PEI Patients
PEI Negative
p Value
Age, mean±sd
54.0±14.9
52.5±16.0
0.383**
Gender
Famele
Male
57(40.1%) / 85(59.9%)89(53.0%)/79 (47.0%)
0.024
PEI Q Test Score, median
0.85
0.57
<0.001*
HbA1c (%), median
6.00
5.50
<0.001*
Vitamin D (ng/mL), median
20
23
0.395*
Fecal Elastase (µg/mL), mean±sd
129.47±72
355.38±101
<0.001**
Diabetes Mellitus, n (%)
39 (27.5%)
25 (14.9%)
0.006
Chronic Pancreatitis, n (%)
5 (3.5%)
5 (3.0%)
0.787
History of Pancreatic Surgery, n (%)
6 (4.2%)
1 (0.6%)
0.032
PEI was identified in 45.8% (n=142) of the cohort, with 43% of these cases classified as severe. PEI was significantly more common in males (p=0.024). Key comorbidities associated with PEI included diabetes mellitus (DM), hypertension (HT), hyperlipidemia (HL), and a history of gastric or pancreatic surgery (Table). Abdominal pain (OR=2.307), bloating (OR=1.667), and particularly malodorous flatus (OR=3.705) were strong predictors of PEI positivity. Ultrasonography showed higher rates of hepatic steatosis and moderate pancreatic steatosis in PEI-positive patients. ROC analysis of the PEI-Q test yielded an AUC of 0.667; a cut-off >0.9 provided 38.7% sensitivity and 89.2% specificity. Furthermore, severe PEI was associated with significantly lower hemoglobin and Vitamin D levels. 65% of PEI patients had complaints before but did not receive a diagnosis.

Conclusion

PEI is common and frequently underdiagnosed in patients with non-specific GI symptoms; high suspicion is warranted, particularly in those with metabolic comorbidities or prior GI surgery.

References

  1. Capurso G, Traini M, Piciucchi M, et al. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol. 2019;12:129–39.
  2. Brydon WG, Kingstone K, Ghosh S. Limitations of faecal elastase‐1 and chymotrypsin as tests of exocrine pancreatic disease in adults. Ann Clin Biochem. 2004;41(1):78–81.
  3. Johnson CD, Arbuckle R, Bonner N, et al. Qualitative assessment of the symptoms and impact of pancreatic exocrine insufficiency (PEI) to inform the development of a patient-reported outcome (PRO) instrument. Patient. 2017;10(5):615-628.

Disclosure

The authors declare no conflict of interest.

Conference

UEG Week Barcelona 2026

Topics

Pancreas

Submission format

Abstract

Session

PANCREAS (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

UEG Presentation
New
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky
PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Aurelio Mauro 1, Alessandro Cappellini 2, Giuseppe Vanella 3, Marco Spadaccini 4, Edoardo Troncone 5, Andrea Lisotti 6, Roberta Badas 7, Raffaele Salerno 8, Roberto Grassia 9, Filippo Antonini 10, Vincenzo Occhipinti 11, Federica Borrelli de Andreis 12, Federico Desideri 13, Germana de Nucci 14, Stefano Mazza 1, Giuseppe Marzocca 3, Miriana Mercurio 15, DAVIDE SCALVINI 2,1, Carlo Fabbri 16, Ilaria Tarantino 17, Andrea Anderloni 2,1

Affiliations

1 San Matteo Hospital Foundation, Pavia, Italy

2 University of Pavia, Pavia, Italy

3 IRCCS San Raffaele Institute, Milan, Italy

4 Humanitas University, Rozzano, Italy

5 University Hospital Policlinico Tor Vergata, Rome, Italy, Rome, Italy

6 Hospital of Imola, University of Bologna, Bologna, Italy

7 University of Cagliari, Cagliari, Italy

8 ASST Fatebenefratelli Sacco, Milan, Italy

9 ASST Cremona, Cremona, Italy

10 Mazzoni Hospital AST Ascoli Piceno, Ascoli Piceno, Italy

11 Papa Giovanni XXIII Hospital, Bergamo, Italy

12 Gemelli Isola - Isola Tiberina Hospital. Catholic University of Sacred Heart, Rome, Italy

13 Ospedale Di Bolzano, Bolzano, Italy

14 ASST Rhodense, Milano, Italy

15 IRCCS Humanitas Research Hospital, Rozzano, Italy

16 AUSL Romagna, Forlì-Cesena Gastroenterology, Bologna, Italy

17 ISMETT, Palermo, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Endoscopic ultrasound (EUS)-guided drainage is a well-established therapeutic option in patients with distal malignant biliary obstruction (DMBO). When duodenal obstruction coexists, transmural drainage from duodenal bulb may increase cholangitis risk. EUS-guided hepaticogastrostomy (EUS-HGS) is often preferred given the anatomical distance from the duodenal stricture, although it is technically demanding and not available in all the centers. Transgastric EUS-guided gallbladder drainage (EUS-GBD) may represent a viable alternative, though data in this setting remain limited.

Aims & Methods

This multicenter retrospective study compared EUS-HGS and transgastric EUS-GBD in patients with DMBO and concomitant duodenal obstruction. Adult patients from 13 Italian referral centers (December 2018–April 2026) were included; those with prior biliary drainage for the same indication were excluded. Management of duodenal obstruction was at endoscopist discretion. Patients included in the present study were unique and not included in previously published study with analogue inclusion criteria.
Primary outcomes were technical and clinical success, the latter defined as a ≥50% reduction in bilirubin within 2 weeks. Secondary outcomes included adverse events (AEs) and reintervention. Categorical variables were compared using Fisher’s exact test.

Results

A total of 101 patients (48.5% F) with a mean age of 70 ± 11.3 years were included. Pancreatic adenocarcinoma was the most common cause of biliary obstruction (73.3%). Duodenal obstruction was most frequently located in the bulb (55.4%). Median follow-up time was 125.5 days (IQR 29-668).
Overall, 67 patients (66.3%) underwent EUS-HGS and 34 (33.7%) transgastric EUS-GBD for biliary drainage. Endoscopic treatment for duodenal obstruction had already been performed in 23.8% of patients prior to biliary drainage (22 EUS-GEA and 2 duodenal stent), while 11.9% underwent treatment afterward (6 EUS-GEA, 4 duodenal stent and one surgical GEA). The remaining patients were asymptomatic and did not require specific treatment for duodenal obstruction. The median direct bilirubin levels decreased from 7.7 mg/dL at baseline to 1.5 mg/dL after biliary drainage.
Technical success was achieved in 99 patients (98%) with no significant difference between EUS-HGS (88.1%) and EUS-GBD (100%) (p=0.54). Clinical success was achieved in 86 patients (85.1%) without significant difference between EUS-HGS and EUS-GBD (88.1% vs 79.4%, respectively p=0.25).
Adverse events (AEs) occurred in 20 patients (19.8%) with comparable rates between EUS-HGS (19.4%) and EUS-GBD (20.6%) (p=1.0). All AEs were post-procedural except for one intra-procedural event. Biliary reintervention was required in 15 patients (14.9%) either by ERCP, EUS or PTBD, occurring more frequently in the EUS-GBD group compared with EUS-HGS (26.5% vs 9% respectively, p=0.03).

Conclusion

In this preliminary multicenter analysis, EUS-GBD achieved outcomes comparable to EUS-HGS with a similar safety profile although a higher reintervention rate was observed in the EUS-GBD group. These findings support its use as a potential alternative in patients with DMBO and concomitant duodenal obstruction especially where HGS is not routinely available. Further prospective studies on larger cohorts are needed to confirm these findings, especially in symptomatic duodenal obstruction given the high rate of asymptomatic obstruction in our cohort of patients.

Disclosure

None

Event

UEG Week Barcelona 2026

Topics

Radiology & Imaging Hepatobiliary Endoscopy

Submission format

Abstract

Session

Endoscopy: Taming the biliary tree

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

UEG Poster
New
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

J. Enrique Domínguez Muñoz 1,2, Yessica Dominguez-Novoa 1,2, José Lariño-Noia 1,2, Peter Jeno Hegyi 3, Gabriele Capurso 4, Xurxo Martinez-Seara 1,2, Orsolya Eperjesi 3, Gaetano Lauri 4, Julio Iglesias-Garcia 1,2

Affiliations

1 University Hospital of Santiago de Compostela, Santiago de Compostela, Spain

2 Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain

3 Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary

4 IRCCS San Raffaele Scientific Institute, Milan, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

The Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) was developed as a patient-reported outcome measure of symptom frequency and intensity in pancreatic exocrine insufficiency (PEI) secondary to chronic pancreatitis (CP) and cystic fibrosis (CF). Its applicability to other PEI etiologies and its value in assessing response to pancreatic enzyme replacement therapy (PERT) have not been established.

Aims & Methods

Aim: To evaluate the performance of the PEI-Q at PEI diagnosis across different aetiologies and its ability to detect response to PERT.
Methods: Patients from the European PEI Registry who completed the PEI-Q at diagnosis and after PERT optimisation were included. PERT efficacy was defined by symptom improvement and normalisation of nutritional status. The PEI-Q comprises 28 items across three domains: abdominal symptoms, bowel symptoms, and quality-of-life (QoL) impact. Each item is scored from 0 (never) to 4 (very frequent/severe), and mean domain and global scores (range 0–4) are calculated. Data are presented as median (range). Group comparisons were performed using Wilcoxon rank-sum, Wilcoxon matched-pairs signed-rank, and Kruskal–Wallis tests.

Results

Ninety-one patients were included (56 male; mean age 62.4±12.0 years). PEI aetiologies were CP (47.2%), pancreatic cancer (18.7%), acute pancreatitis (16.5%), pancreatectomy (13.2%), and others (4.4%). At diagnosis, the median global PEI-Q score was 0.8 (0–3.1), with no significant differences between aetiologies. Following PERT optimisation, the global score decreased to 0.3 (0–2.7) (p<0.001), irrespective of aetiology, with consistent improvements observed across all domains.

Conclusion

The PEI-Q reliably quantifies symptom burden across diverse PEI aetiologies and demonstrates responsiveness to PERT. These findings support its utility as a patient-reported outcome measure in both clinical practice and research.

Disclosure

J. Enrique Domínguez, international advisor for Viatris
Julio Iglesias-Garcia, international advisor for Viatris
Yessica Dominguez-Novoa, international advisor for Viatris
Jose Lariño-Noia, international advisor for Viatris

Conference

UEG Week Barcelona 2026

Topics

Pancreas

Submission format

Abstract

Session

Chronic pancreatitis: Triggers, treatment, and challenges (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

UEG Poster
New
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Marta Andreozzi 1, Federico Cassano 1, Mark Policane 1, Maria Terrin 1, Marco Spadaccini 1, Federico Caldart 2, Nicolò de Pretis 3, Marco Sacco 4, Simone Dibitetto 4, Luca Frulloni 3, Cesare Hassan 5, Alessandro Repici 6, Silvia Carrara 1

Affiliations

1 Humanitas Research Hospital, Milano, Italy

2 Verona University Hospital - University of Verona, Padova, Italy

3 University of Verona - Gastroenterology and Endoscopy Unit, Verona, Italy

4 AOU Città della Salute e della Sicenza di Torino, University of Turin, 10126 Turin, Italy, Turin, Italy

5 Humanitas University, Pieve Emanuele MI, Italy

6 Ist. Clinico Humanitas Rozzano Dept. of Gastroenterology, Milano, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Fecal elastase-1 (FE-1) is widely used to diagnose exocrine pancreatic insufficiency (EPI), but its utility in patients without risk factors is unclear.

Aims & Methods

We conducted a multicenter retrospective study including 824 patients referred to gastroenterology clinics who underwent FE-1 testing. Patients were stratified according to the presence of established EPI risk factors (chronic pancreatitis, recurrent acute pancreatitis, pancreatic cancer, pancreatic surgery, alcohol abuse). Indications for testing, FE-1 levels, final diagnoses, and pancreatic enzyme replacement therapy (PERT) prescriptions were analysed.

Results

Among 824 patients, 539 (65%) had no risk factors and 285 (35%) had at least one risk factor for EPI. In patients without risk factors, testing was mainly prompted by non-specific symptoms such as diarrhoea (22%) and abdominal pain (34%). In contrast, patients with established risk factors often did not present with gastrointestinal symptoms (65 % asymptomatic).
FE-1 <100 µg/g was more frequent in at-risk patients (52% vs 27%), as was FE-1 <200 µg/g (59% vs 39%). Confirmed EPI (defined by at least 2 of the following: FE-1 <100 µg/g, steatorrhea, consistent pancreatic imaging) was significantly higher in the risk group (47% vs 19%). The positive predictive value (PPV) of FE-1 <200 µg/g was ~80% in at-risk patients versus ~50% in patients without risk factors.
PERT was prescribed in 299 patients (38%), with inappropriate prescriptions (PERT without confirmed EPI) more frequent in patients without risk factors (40% vs 16%).

Conclusion

The diagnostic yield of FE-1 for EPI strongly depends on pre-test probability. In patients without pancreatic risk factors, testing is often driven by non-specific symptoms, leading to low diagnostic accuracy and substantial overtreatment. In contrast, in patients with established risk factors, EPI may often be subclinical and therefore warrants proactive testing.

Conference

UEG Week Barcelona 2026

Topics

Pancreas

Submission format

Abstract

Session

Pancreatic cancer: Striving for survival (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

UEG Poster
New
Standard Poster
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

Connor Cotton 1, Arkadeep Dhali 1, Cristina Caranfil 1, Peter Evans 2, Bethany Brailsford 2, Francesca Manza 3, Pashmi H. D. Liyanage 4, Anju Gurung 2, Aishwarya Devanand 1, Suneil Raju 1, Gregory Naylor 2, David Surendran Sanders 1

Affiliations

1 Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, United Kingdom

2 Chesterfield Royal Hospital, Chesterfield, United Kingdom

3 University of Ferrara, Ferrara, Italy

4 University of Pavia, Pavia, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Introduction

Pancreatic involvement in inflammatory bowel disease (IBD) is increasingly recognised but remains poorly defined, particularly pancreatic exocrine insufficiency (PEI). Reported prevalence varies widely, and interpretation of faecal elastase-1 (FE-1) is limited by concerns regarding falsely low values in diarrhoeal states.

Aims & Methods

We aimed to determine the prevalence of PEI in an unselected IBD cohort and evaluate associations with disease phenotype, inflammatory markers and clinical outcomes, while accounting for diarrhoeal confounding.
A dual-centre retrospective cohort study of IBD patients undergoing FE-1 testing was performed, including those tested between 2018–2023 at one centre and 2022–2024 at the other. PEI was defined as FE-1 <200 µg/g (moderate 100–199 µg/g; severe <100 µg/g). Associations with disease subtype, extent, inflammatory markers, symptoms, and therapy were assessed. A predominant colonic phenotype was defined as Crohn’s disease (CD) L2 or ulcerative colitis (UC) E2/E3. Multivariable logistic regression assessed predictors of low FE-1, adjusting for diarrhoea, bowel frequency, and inflammatory markers. Response to pancreatic enzyme replacement therapy (PERT) and imaging findings were evaluated.

Results

Eighty-seven patients were included (median age 60 years [IQR 46-72]; 56.3% CD, 41.4% UC and 2.3% IBD unclassified). PEI was identified in 19/87 (21.8%), with similar prevalence in CD (22.4%) and UC (19.4%); 11.5% had moderate (100–199 µg/g) and 10.3% severe (<100 µg/g) PEI.
Male sex (OR 6.45, p=0.002) and increasing age (OR 1.56 per decade, p=0.036) were associated with low FE-1. FE-1 correlated negatively with CRP (ρ=−0.249, p=0.039).
Among CD patients, disease location was significantly associated with FE-1, with colonic CD (L2) demonstrating the highest PEI prevalence (41.7%), compared with 18.2% in ileocolonic (L3) and 10.0% in ileal (L1) disease (p=0.009). In UC, PEI was observed in 25.0% of E3, 22.2% of E2, and 0% of E1 disease.
Treating FE-1 as a continuous variable, levels were significantly lower in patients with a colonic phenotype (L2, E2 and E3) compared to those without (median 431 [IQR 172–500] vs 500 [IQR 484–500] µg/g; p=0.022).
In multivariable analysis, a colonic phenotype remained independently associated with low FE-1 after adjustment for diarrhoea (adjusted OR 1.90, p=0.044), bowel frequency, and inflammatory markers.
Diarrhoea was not associated with low FE-1 (22.5% in patients with diarrhoea vs 18.8% without; OR 1.26, p=1.00), and bowel frequency showed no correlation (ρ=−0.035, p=0.776).
Among patients with low FE-1, 10/19 (52.6%) had structural pancreatic abnormalities, most commonly atrophy (36.8%). Of those treated with PERT, 8/12 (66.7%) reported symptomatic improvement.

Conclusion

PEI was identified in approximately one in five patients with IBD in this cohort, and reduced FE-1 was not explained by diarrhoeal dilution or bowel frequency, supporting the presence of true pancreatic dysfunction. Colonic disease phenotype was associated with low FE-1, with consistent findings across multivariable and continuous analyses. Correlation with CRP suggests a link with inflammatory activity. Structural abnormalities are common but often non-specific, and symptomatic improvement with PERT supports clinical relevance. These findings support consideration of PEI in symptomatic IBD patients with ongoing gastrointestinal symptoms and warrant prospective evaluation.

Conference

UEG Week Barcelona 2026

Topics

Pancreas

Submission format

Abstract

Session

PANCREAS (Posters)

Citation

2026: United European Gastroenterology Journal 2026; 14 (S1)

Published

2026

More Like This:

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

REAL-WORLD EVALUATION OF SUSPECTED PANCREATIC EXOCRINE INSUFFICIENCY AND GENERATION OF A REASONABLE WORKUP

Georg Beyer Georg Beyer, Julia Mayerle, Hans Stubbe, Simon Sirtl, Marlies Vornhülz, Liva Rudroff, Tobias Jens, Jakob Vielhauer

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

HIGH FREQUENCY OF PANCREATIC EXOCRINE INSUFFICIENCY AMONG PATIENTS WITH COMMON GASTROINTESTINAL SYMPTOMS: HIDDEN PANCREATIC INSUFFICIENCY

Damla Hazal Sucu Damla Hazal Sucu, Orhan Sezgin, Gizem Sultan Kürtül

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

PRELIMINARY RESULTS OF THE GIANUS STUDY: EUS-GUIDED HEPATICOGASTROSTOMY VERSUS EUS-GUIDED TRANSGASTRIC GALLBLADDER DRAINAGE FOR MALIGNANT BILIARY AND DUODENAL OBSTRUCTION

Andrea Anderloni Andrea Anderloni, Ilaria Tarantino, Carlo Fabbri, DAVIDE SCALVINI, Miriana Mercurio, Giuseppe Marzocca, Stefano Mazza, Germana de Nucci, Federico Desideri, Federica Borrelli de Andreis, Vincenzo Occhipinti, Filippo Antonini, Roberto Grassia, Raffaele Salerno, Roberta Badas, Andrea Lisotti, Edoardo Troncone, Marco Spadaccini, Giuseppe Vanella, Alessandro Cappellini, Aurelio Mauro

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

IS THE PEI-Q A UNIVERSAL PATIENT-REPORTED OUTCOME MEASURE FOR PANCREATIC EXOCRINE INSUFFICIENCY? VALIDATION ACROSS AETIOLOGIES AND RESPONSE TO PANCREATIC ENZYME REPLACEMENT THERAPY

Julio Iglesias-Garcia Julio Iglesias-Garcia, Gaetano Lauri, Orsolya Eperjesi, Xurxo Martinez-Seara, Gabriele Capurso, Peter Jeno Hegyi, José Lariño-Noia, Yessica Dominguez-Novoa, J. Enrique Domínguez Muñoz

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

RISK-STRATIFIED UTILITY OF FECAL ELASTASE-1 AND PANCREATIC ENZYME THERAPY IN CLINICAL PRACTICE: INSIGHTS FROM A MULTICENTER ITALIAN RETROSPECTIVE ANALYSIS

Silvia Carrara Silvia Carrara, Alessandro Repici, Cesare Hassan, Luca Frulloni, Simone Dibitetto, Marco Sacco, Nicolò de Pretis, Federico Caldart, Marco Spadaccini, Maria Terrin, Mark Policane, Federico Cassano, Marta Andreozzi

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

PANCREATIC EXOCRINE INSUFFICIENCY IN INFLAMMATORY BOWEL DISEASE IS NOT EXPLAINED BY DIARRHOEAL DILUTION: A DUAL-CENTRE STUDY USING FAECAL ELASTASE

David Surendran Sanders David Surendran Sanders, Gregory Naylor, Suneil Raju, Aishwarya Devanand, Anju Gurung, Pashmi H. D. Liyanage, Francesca Manza, Bethany Brailsford, Peter Evans, Cristina Caranfil, Arkadeep Dhali, Connor Cotton

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.